Ixekizumab for the treatment of psoriasis: up-to-date

References

• Griffiths CEM, van der Walt JM, Ashcroft DM, et al. The global state of psoriasis disease epidemiology: a workshop report. Br J Dermatol. 2017;177:e4–e7. Blackwell Publishing Ltd.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64:14–17.
   Web of Science ®Google Scholar
• Brembilla NC, Senra L, Boehncke WH. The IL-17 family of cytokines in psoriasis: IL-17A and beyond. Front Immunol. 2018;9:1682. DOI:10.3389/fimmu.2018.01682.
   PubMed Web of Science ®Google Scholar
• Malakouti M, Brown GE, Wang E, et al. The role of IL-17 in psoriasis. J Dermatological Treat. 2015;26:41–44.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Kalb RE, Blauvelt A, et al. The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study. J Am Acad Dermatol. 2012;67:642–650.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55:379–390.
   PubMed Web of Science ®Google Scholar
• Lai Y, Li D, Li C, et al. The antimicrobial protein REG3A regulates keratinocyte proliferation and differentiation after skin injury. Immunity. 2012;37:74–84.
   PubMed Web of Science ®Google Scholar
• Gutowska-Owsiak D, Schaupp AL, Salimi M, et al. IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion. Exp Dermatol. 2012;21:104–110.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M, et al. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol. 2011;131:677–687.
   PubMed Web of Science ®Google Scholar
• Company, E.-L. and prescribing information ixekizumab. 2019. [cited 2019 Dec 10]. Available from: http://uspl.lilly.com/taltz/taltz.html#pi
   Google Scholar
• Giunta A, Ventura A, Chimenti MS, et al. Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy. Drug Des Devel Ther. 2017;11:1643–1651.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366:1190–1199.
   PubMed Web of Science ®Google Scholar
• Papp KA, Leonardi CL, Blauvelt A, et al. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). Br J Dermatol. 2018;178:674–681.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375:345–356.
   PubMed Web of Science ®Google Scholar
• Agency, E. M. Committee for medicinal products for human use (CHMP) assessment report. 2016. [cited 2019 Dec 10]. Available from: www.ema.europa.eu/contact.
   Google Scholar
• Leonardi C, Maari C, Philipp S, et al. Maintenance of skin clearance with ixekizumab treatment of psoriasis: three-year results from the UNCOVER-3 study. J Am Acad Dermatol. 2018;79:824–830.e2.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Lacour JP, Korman N, et al. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies. J Eur Acad DermatolVenereol. 2017;31:679–685.
   PubMed Web of Science ®Google Scholar
• Warren RB, Barker J, Finlay AY, et al. Secukinumab for patients failing previous TNFα‐inhibitor therapy: results of a randomised open-label study (Signature). Br J Dermatol. 2019. bjd.18623. DOI:10.1111/bjd.18623.
   Google Scholar
• Warren RB, Smith CH, Yiu ZZN, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: A prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015;135:2632–2640.
   PubMed Web of Science ®Google Scholar
• Reich K, Pinter A, Lacour JP, et al. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. Br J Dermatol. 2017;177:1014–1023.
   PubMed Web of Science ®Google Scholar
• Paul C, Griffiths CEM, van de Kerkhof PCM, et al. Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: results from IXORA-S, a phase 3 study. J Am Acad Dermatol. 2019;80:70–79.e3.
   PubMed Web of Science ®Google Scholar
• Biospace. New head-to-head data show Taltz® (ixekizumab) superiority versus TREMFYA® (guselkumab) in people with moderate to severe plaque psoriasis | bioSpace. [cited 2019 Dec 10]. Available from: https://www.biospace.com/article/releases/new-head-to-head-data-show-taltz-ixekizumab-superiority-versus-tremfya-guselkumab-in-people-with-moderate-to-severe-plaque-psoriasis/.
   Google Scholar
• Blauvelt A, Langley R, Gordon K, et al. Ixekizumab, a novel anti–IL-17A antibody, exhibits low immunogenicity during long-term treatment in patients with psoriasis. J Am Acad Dermatol. 2016;74:AB258.
   Web of Science ®Google Scholar
• Griffiths CEM, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386:541–551.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Burlando M, Caldarola G, et al. Ixekizumab effectiveness and safety in the treatment of moderate-to-severe plaque psoriasis: a multicenter, retrospective observational study. Am J Clin Dermatol. 2019. DOI:10.1007/s40257-019-00490-2.
   PubMed Web of Science ®Google Scholar
• Deza G, Notario J, Lopez-Ferrer A, et al. Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study. J Eur Acad DermatolVenereol. 2019;33:553–559.
   PubMed Web of Science ®Google Scholar
• Magdaleno-Tapial J, Carmena-Ramón R, Valenzuela-Oñate C, et al. Efficacy and safety of Ixekizumab in a real-life practice: a retrospective bicentric study. Actas Dermo-Sifiliográficas (English Ed). 2019;110:585–589.
   PubMed Web of Science ®Google Scholar
• Megna M, Cinelli E, Balato A, et al. Efficacy and safety of ixekizumab in a group of 16 elderly patients with psoriasis over a 1-year period. J Eur Acad Dermatol Venereol. 2020. jdv.16063. DOI:10.1111/jdv.16063.
   PubMedGoogle Scholar
• Damiani G, Conic RRZ, Pigatto PDM, et al. From randomized clinical trials to real life data. An Italian clinical experience with ixekizumab and its management. Dermatol Ther. 2019;32(3):e12886. DOI:10.1111/dth.12886.
   Web of Science ®Google Scholar
• Langley RG, Kimball AB, Nak H, et al. Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials. J Eur Acad DermatolVenereol. 2019;33:333–339.
   PubMedGoogle Scholar
• Blauvelt A, Gooderham M, Iversen L, et al. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). J Am Acad Dermatol. 2017;77:855–862.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. 【ERASURE study group; FIXTURE study group】Secukinumab in plaque psoriasis — results of two Phase 3 trials. N Engl J Med. 2014;371:326–338.
   Google Scholar
• Wang J, Bhatia A, Cleveland NK, et al. Rapid onset of inflammatory bowel disease after receiving secukinumab infusion. ACG Case Reports J. 2018;5:e56.
   PubMed Web of Science ®Google Scholar
• Ryan C, Menter A, Guenther L, et al. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. Br J Dermatol. 2018;179:844–852.
   PubMed Web of Science ®Google Scholar
• A study of Ixekizumab (LY2439821) in participants with moderate-to-severe genital psoriasis - full text view - clinicalTrials.gov. [cited 2019 Dec 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT02718898.
   Google Scholar
• Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365:620–628.
   PubMed Web of Science ®Google Scholar
• Morita A, Yamazaki F, Matsuyama T, et al. Adalimumab treatment in Japanese patients with generalized pustular psoriasis: results of an open-label phase 3 study. J Dermatol. 2018;45:1371–1380.
   PubMed Web of Science ®Google Scholar
• Almutairi D, Sheasgreen C, Weizman A, et al. Generalized pustular psoriasis induced by infliximab in a patient with inflammatory bowel disease. J Cutan Med Surg. 2018;22:507–510.
   PubMed Web of Science ®Google Scholar
• Wilsmann-Theis D, Schnell LM, Ralser-Isselstein V, et al. Successful treatment with interleukin-17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations. J Dermatol. 2018;45:850–854.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Van Der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76:79–87.
   PubMed Web of Science ®Google Scholar
• Nash P, Kirkham B, Okada M, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389:2317–2327.
   PubMed Web of Science ®Google Scholar
• Administration, F. and D. TALTZ (ixekizumab) Injection. 2016. [cited 2019 Dec 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/125521Orig1s000TOC.cfm
   Google Scholar
• FDA. TALTZ (ixekizumab) injection, for subcutaneous use. [cited 2019 Dec 10]. Available from: www.fda.gov/medwatch.
   Google Scholar
• CHMP. EPAR summary for the public. [cited 2019 Dec 10]. Available from: www.ema.europa.eu/contact.
   Google Scholar
• Sawyer LM, Malottki K, Sabry-Grant C, et al. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response. PLoS One. 2019;14:e0220868.
   PubMed Web of Science ®Google Scholar
• Mason KJ, Barker J, Smith C, et al. Comparison of drug discontinuation, effectiveness, and safety between clinical trial eligible and ineligible patients in BADBIR. JAMA Dermatol. 2018;154:581–588.
   PubMed Web of Science ®Google Scholar
• Kammüller M, Tsai TF, Griffiths CEM, et al. Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections. Clin Transl Immunol. 2017;6:e152.
   PubMed Web of Science ®Google Scholar
• Xie X, Li F, Chen JW, et al. Risk of tuberculosis infection in anti-TNF-α biological therapy: from bench to bedside. J Microbiol Immunol Infect. 2014;47:268–274.
   PubMedGoogle Scholar